Logo Division of Drug Synthesis
Department of Pharmaceutical Chemistry
Faculty of Life Sciences, University of Vienna
Logo Uni Wien

Adenosine A3 Antagonists as PET-Diagnostics

The A3AR is discussed to be involved in a variety of pathologies. At present PET is the most sensitive method for the purpose of functional imaging and the prosperity of this method is carried by innovation in the development of new tracers and by the evaluation of new receptors as targets for these tracers. The limitation of the PET-technique lies in the supply of potent and specific radiotracers for specific applications. Since the A3AR promises to be a specific target for various clinical questions (especially of neuro-/psychiatric, cardiological and oncological nature) and the chosen PET tracer proves high affinity and selectivity for the target, the present study can provide the basis for several implications:
  1. the safe use of this [18F] in further clinical studies
  2. potentially, the quality of the imaging of oncological, cardiac and neuro/psychiatric pathologies can be performed with higher sensitivity and specificity (taking into consideration that existing PET tracers such as [18F]FDG, [18F]FLT, [18F]fluorocholine etc. are of limited specificity in the discussed oncological applications])
  3. a further insight and better understanding in the involvement of the A3AR in various neurotransmitter systems can be obtained; this could provide a basis for the development of novel psycho pharmaceuticals
  4. development of a new working standard for the evaluation of the A3AR as a potential binding site of atypical neuroleptics using PET
18F

[back]